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Abstract
Background:  Systemic sclerosis (SSc) is an autoimmune disorder of the connective tissue
characterized by widespread vascular lesions and fibrosis. Little is known so far on the activation
of the hemostatic and fibrinolytic systems in SSc, and most preliminary evidences are discordant.
Methods: To verify whether SSc patients might display a prothrombotic condition, plasma D-
dimer was assessed in 28 consecutive SSc patients and in 33 control subjects, matched for age, sex
and environmental habit.
Results and discussion: When compared to healthy controls, geometric mean and 95%
confidence interval (IC95%) of plasma D-dimer were significantly increased in SSc patients (362 ng/
mL, IC 95%: 361–363 ng/mL vs 229 ng/mL, IC95%: 228–231 ng/mL, p = 0.005). After stratifying SSc
patients according to disease subset, no significant differences were observed between those with
limited cutaneous pattern and controls, whereas patients with diffuse cutaneous pattern displayed
substantially increased values. No correlation was found between plasma D-dimer concentration
and age, sex, autoantibody pattern, serum creatinine, erythrosedimentation rate, nailfold
videocapillaroscopic pattern and pulmonary involvement.
Conclusion:  We demonstrated that SSc patients with diffuse subset are characterized by
increased plasma D-dimer values, reflecting a potential activation of both the hemostatic and
fibrinolytic cascades, which might finally predispose these patients to thrombotic complications.
Background
Systemic sclerosis (SSc) is an autoimmune disorder of the
connective tissue characterized by widespread vascular
lesions and fibrosis. In SSc, vasospasm causes frequent
episodes of reperfusion injury and free radical-mediated
endothelial dysfunction, which might finally influence
the onset of local thrombotic complications. The charac-
teristic vascular involvement affects primarily small arter-
ies and capillaries, causing reduced blood flow and tissue
ischemia and supporting the typical clinical manifesta-
tions of this unique autoimmune disorder [1]. However,
mechanisms involved in the endothelial injury are as yet
elusive and most biochemical evidences are often incon-
clusive or controversial. Some earlier investigations sug-
gested that SSc patients might be characterized by a
procoagulant state, reporting depressed basal and stimu-
lated fibrinolytic activity, while others studies have
reported normal plasma fibrinolytic activity and normal
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skin and plasma tissue plasminogen activator (tPA) levels
[2-4]. It has been also reported that the lack of a consistent
and homogenous increase of some fibrinolytic markers,
in the presence of normal levels of antithrombin, might
indirectly highlight an impairment of the heparan sul-
phate-antithrombin system, which would finally promote
thrombin generation [3]. Conversely, Cerinic and col-
leagues provided evidence that fibrinolysis might be
impaired in SSc, as shown by reduced D-dimer and
decreased levels of plasminogen activator inhibitor [4]. In
synthesis, there are no conclusive evidences on the activity
of the hemostatic and fibrinolytic pathways in SSc so far.
D-dimer, a breakdown product of cross-linked fibrin, was
proven useful for the diagnostic evaluation of several
thrombotic disorders. Moreover, an increased D-dimer
value in plasma is a reliable marker of a systemic pro-
thrombotic state, likely superior to alternative fibrinolytic
markers, and its measurement might be helpful in predict-
ing or preventing thrombotic events in the single patient
[5]. Therefore, to investigate whether SSc patients might
be characterized by a potential prothrombotic condition,
plasma D-dimer vales were measured in a subset of SSc
patients, compared with those of a healthy matched con-
trol population and further associated with SSc disease
subset.
Methods
Plasma D-dimer was measured in 28 consecutive SSc
patients (2 males and 26 females; mean age 50 ± 15 years,
17 with limited and 11 with diffuse disease patterns), who
fulfilled the American Rheumatism Association's criteria
for the diagnosis of SSc [6] and in 33 control subjects,
matched for age (48 ± 13 years), sex (3 males, 30 females)
and environmental habit, recruited among healthy hospi-
tal personnel. Samples were collected in the morning; all
subjects were in a fasted state. The research was carried out
according to the principles of the Declaration of Helsinki
and an informed consent for testing was received from all
individuals recruited to the study. Blood was collected
after an overnight fast into siliconized vacuum tubes, con-
taining 0.105 mol/l sodium citrate (Becton-Dickinson,
Oxford, UK). Samples were gently mixed and centrifuged
for 10 min at 15°C at 1500 × g; plasma was separated and
stored in aliquots at -70°C until measurement. Plasma D-
dimer was measured employing Vidas DD, a rapid and
quantitative automated enzyme linked immunosorbent
assay with fluorescent detection, on the Mini Vidas immu-
noanalyzer (bioMerieux, Marcy l'Etoile, France). Analyti-
cal imprecision, expressed in terms of mean inter-assay
coefficient of variation (CV), was quoted by the manufac-
turer as being lower than 5%. Significance of differences
between samples was assessed, following logarithmic con-
version of data, by parametric tests (Student's t-test,
ANOVA test, Pearson's correlation); the level of statistical
significance was set at p < 0.05.
Results and discussion
When compared to healthy controls, geometric mean and
95% confidence interval (IC95%) of plasma D-dimer
concentration appeared significantly increased in SSc
patients (362 ng/mL, IC 95%: 361–363 ng/mL vs 229 ng/
mL, IC95%: 228–231 ng/mL, p = 0.005). After stratifying
SSc patients according to disease subset, no significant dif-
ferences were observed between those with limited cuta-
neous pattern (lcSSc) and controls (geometric mean
plasma D-dimer: 283 ng/mL, IC95%: 282–285 ng/mL; p
= 0.61), whereas patients with diffuse cutaneous pattern
(dcSSc) displayed substantially increased values (geomet-
ric mean plasma D-dimer: 538 ng/mL, IC95%: 536–539
ng/mL; p < 0.001). Additionally, patients with active dis-
ease, as evaluated according to the European Scleroderma
Study Group criteria [7], displayed higher D-dimer levels
as compared to patients with inactive disease (p = 0.027).
As further shown in table 1, D-dimer concentration corre-
lated significantly with the modified Rodnan total skin
score (TSS) and the forced vital capacity (FVC). No corre-
lation was observed between plasma D-dimer concentra-
tion and age, sex, autoantibody pattern, serum creatinine,
erythrosedimentation rate, nailfold videocapillaroscopic
pattern and pulmonary involvement, ascertained accord-
ing to the score proposed by Medsger et al [8].
Table 1: Plasma D-dimer values and association with clinical features in 28 patients with systemic sclerosis (SSc) and 33 healthy 
matched controls (values are expressed as geometric mean and 95% interval of confidence).
D-dimer (ng/mL) p
Patients subset Controls (n = 33) 229 (228–231) 0.005
SSc patients (n = 28) 362 (361–363)
Clinical subset Limited SSc (n = 17) 283 (282–285) 0.015
Diffused SSc (n = 11) 538 (536–539)
Disease activity Inactive SSc (n = 20) 306 (305–308) 0.027
Active SSc (n = 8) 562 (560–564)
Total skin score r = 0.63* <0.001
Forced vital capacity r = 0.45* 0.016
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The pathogenesis of the endothelial injury in SSc is as yet
elusive and most biochemical evidences are often incon-
clusive or controversial. Although endothelial cell apop-
tosis and impaired angiogenesis have received major
attention among the mechanisms involved in the charac-
teristic vascular dysfunction, recent studies provided clear
evidence of a significant activation of the coagulation cas-
cade, resulting in a procoagulant state that might finally
raise the relative risk of thrombotic events in these
patients. In SSc, the peculiar vascular lesions and fibrosis
were claimed to impair endothelial function, as suggested
by impairment of fibrinolysis and activation of the coagu-
lation pathway. The following loss of the balance between
fibrinolysis and coagulation might finally contribute to
vessel engulfment with fibrin and breakdown of vessel
patency, symptomatic of a tendency to the development
of thrombotic complications in this particular autoim-
mune disorder [4]. D-dimer is a heterogeneous class of
end-stage degradation products that directly reflect the
level of lysed cross-linked fibrin, occurring in vivo with a
wide range of molecular weights. Therefore, D-dimer is a
well-recognized marker of a systemic prothrombotic state
[5,9] and appears a strong, consistent predictor of cardio-
vascular events in the general population, in patients with
cardiovascular disease and in other pathologies character-
ized by an increased risk of thrombosis [10-12]. Accord-
ingly, D-dimer measurement could be reliably used as an
initial screening test in patients with clinically suspected
thrombosis, as its high negative predictive value enables
to validly rule out ongoing thrombotic complications
[12]. Little is known on the thrombotic tendency of SSc
patients so far [13]. At variance with previous investiga-
tions [2-4], we demonstrated that SSc patients with diffuse
subset are characterized by increased plasma D-dimer val-
ues, reflecting a potential activation of both the coagula-
tion and fibrinolytic pathways.
Conclusion
Although increased D-dimer values in SSc patients were
occasionally observed in earlier studies, the association
between plasma D-dimer and disease subset is likely an
original and innovative issue. The significant correlation
observed with disease activity, cutaneous involvement
and forced vital capacity, further suggests that SSc
patients, especially those with diffuse subset, display a
hypercoagulable state, which might finally predispose this
peculiar subset of patients to the development of throm-
botic complications.
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